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Abstract  
Background: Asenapine is a new pharmacological agent for the acute treatment of 
schizophrenia and bipolar disorder. It has relatively higher affinity for serotonergic and 
α2-adrenergic than dopaminergic D2 receptors. We evaluated the effects of asenapine, 
risperidone, and olanzapine on acute and subchronic psychotomimetic-induced disruption 
of cued reversal learning in rats. 
Methods: After operant training, rats were treated acutely with D-amphetamine (0.75 
mg/kg intraperitoneally [i.p.]) or phencyclidine (PCP; 1.5 mg/kg i.p.) or sub-chronically 
with PCP (2 mg/kg i.p. for 7 days). We assessed the effects of acute coadministration of 
asenapine, risperidone, or olanzapine on acute D-amphetamine– and PCP-induced deficits 
and the effects of long-term coadministration of these agents (for 28 additional days) on 
the deficits induced by subchronic PCP. 
Results: Deficits in reversal learning induced by acute D-amphetamine were attenuated 
by risperidone (0.2 mg/kg i.p.). Acute PCP-induced impairment of reversal learning was 
attenuated by acute asenapine (0.025 mg/kg subcutaneously [s.c.]), risperidone (0.2 
mg/kg i.p.), and olanzapine (1.0 mg/kg i.p.). Subchronic PCP administration induced an 
enduring deficit that was attenuated by acute asenapine (0.075 mg/kg s.c.) and by 
olanzapine (1.5 mg/kg i.p.). Asenapine (0.075 mg/kg s.c.), risperidone (0.2 mg/kg i.p.), 
and olanzapine (1.0 mg/kg i.p.) all showed sustained efficacy with chronic (29 d) 
treatment to improve subchronic PCP-induced impairments. 
Conclusion: These data suggest that asenapine may have beneficial effects in the 
treatment of cognitive symptoms in schizophrenia. However, this remains to be validated 
by further clinical evaluation.  
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INTRODUCTION 
Cognitive dysfunction is a core component of schizophrenia [19]. Deficits 
affecting attention, perception, executive function, and memory may even be present in 
schizophrenics experiencing their first psychotic episode [34]. These cognitive deficits 
have significant bearing on patient recovery, functional capacity, and societal 
reintegration [4,8,9]. 
Given the negative impact of cognitive dysfunction on long-term patient function 
and quality of life, the lack of reliably effective treatment is considered to be a key unmet 
clinical need [16]. However, the clinical literature has generally reported no consistent, 
substantial improvement in cognition with the current pharmacotherapies for 
schizophrenia [20,42]. In one long-term naturalistic study, the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) study, some antipsychotics produced small 
but statistically significant improvements in cognition [32]. In further recognition of the 
need to address cognitive dysfunction in patients with schizophrenia and to encourage the 
development of cognition-enhancing drugs for schizophrenia, the National Institute of 
Mental Health, in collaboration with the University of California at Los Angeles and the 
US Food and Drug Administration, initiated the Measurement and Treatment Research to 
Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on 
Neurocognition and Schizophrenia (TURNS) programs. 
Preclinical studies have routinely demonstrated that second-generation 
antipsychotics (SGAs) enhance cognitive function in animal models that assess reversal 
learning, working and nonspatial memory, and selective attention [1-
3,11,18,24,25,35,39,55,56]. In a rodent operant reversal-learning paradigm based on tasks 
developed by Smith et al [48] and Jones et al [30], deficits in reversal learning produced 
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by phencyclidine (PCP) were attenuated by the SGAs clozapine, ziprasidone, and 
olanzapine, but not by the first-generation antipsychotics haloperidol or chlorpromazine 
[2,3,25]. Similarly, deficits in novel object recognition and attentional set shifting 
induced by 7 days of treatment with PCP are reversed by clozapine and risperidone but 
not by haloperidol [18,39]. Importantly, doses of SGAs that attenuate the effects of PCP 
do not generally have an effect on reversal learning in nonimpaired rats, and we have 
recently demonstrated lack of impairment in control rats treated with clozapine and 
risperidone at doses that improve PCP-induced deficits, including the doses of 
risperidone shown to be effective in the present study [40]. 
Cognitive deficits induced by drugs affecting glutamatergic function—in 
particular, N-methyl-D-aspartate (NMDA) receptor antagonists such as PCP and 
ketamine—mimic cognitive dysfunction in schizophrenia [7,27,33]. These findings 
support the NMDA hypothesis of schizophrenia, which proposes that cognitive deficits in 
schizophrenics may be partially attributed to NMDA receptor hypofunction [43]. 
Therefore, inducing cognitive deficits with subchronic PCP treatment may be useful for 
assessing the treatment of cognitive dysfunction in schizophrenia [26,29]. 
Asenapine is a novel psychopharmacologic agent recently approved for the 
treatment of schizophrenia and bipolar disorder. It has been shown to be effective and 
well tolerated in the treatment of schizophrenia [44] and mania in bipolar disorder 
patients [38]. It shows nanomolar level binding and antagonist activity at cloned human 
serotonin (5-HT; 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5, 5-HT6, 5-HT7,), 
dopamine (D1, D2, D3, D4), -adrenergic (1A, 2A, 2B, 2C), and histamine (H1, H2) 
receptors but minimal affinity for muscarinic receptors [46,47]. In particular, asenapine 
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has higher affinity for some serotonergic (5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, 5-HT7), 
adrenergic (2B), and dopamine receptors (D3) when compared with dopamine D2 
receptors [47]. 
In this report, we assess the effects of asenapine on reversal-learning deficits 
induced by acute PCP or D-amphetamine, or subchronic PCP. Because modulation of 
dopaminergic and glutamatergic activity may be mediated through antagonism of 5-HT 
receptors, it was hypothesized that asenapine would exhibit beneficial effects in these 
models of psychomimetic-induced cognitive deficits. The effects of olanzapine and 
risperidone monotherapy were independently examined to provide comparators for 
asenapine. Both have shown efficacy to reverse PCP-induced impairments in this and 
other models [1,18,39,41]; however, neither has previously been tested against D-
amphetamine–induced cognitive deficits.  
 
MATERIALS AND METHODS 
Animals 
Adult female Lister hooded rats (n=100 in all 3 studies combined) obtained from 
Harlan, UK, were used in these studies. Female rats were used because they show robust 
cognitive deficits induced by PCP in several other paradigms and perform better in 
certain cognitive tasks compared with male rats [50,51]. Stage of the estrous cycle does 
not affect the ability of rats to perform in novel object recognition or reversal-learning 
tasks [40,50].  
Rats were housed in groups (4–5 per cage) and maintained under standard 
laboratory conditions (temperature, 21°±2° C; humidity, 40%–50%). A 12-hour 
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light/dark cycle (lights on at 7:00 AM) was maintained. All procedures were performed 
during the light phase. All rats were reduced to approximately 85% of their free-feeding 
body weight (225–250 g) before each study and maintained at this weight by restricting 
food access to 12 g/d of standard laboratory chow (Special Diet Services, Essex, UK). 
Free access to water was provided. All experiments were conducted in accordance with 
the Animals (Scientific Procedures) Act, UK, of 1986 and approved by the University of 
Bradford ethical review process. 
 
Drugs 
Asenapine, olanzapine, and risperidone were supplied by Schering-Plough 
Corporation (Newhouse, Lanarkshire, UK). Asenapine was dissolved in 0.9% saline and 
administered subcutaneously (s.c.). Asenapine was given s.c. in an attempt to provide a 
surrogate for the sublingual route used in clinical studies [44], as well as for consistency 
with other preclinical studies that have assessed the effects of asenapine [15,23,53,54]. 
Olanzapine and risperidone were dissolved in a small volume of acetic acid, adjusted to 
their final concentration with 0.9% saline, pH-adjusted to 5.5 to 6.0 with 0.1 M NaOH, 
and administered intraperitoneally (i.p.). PCP hydrochloride and D-amphetamine sulfate 
(Sigma-Aldrich, Irvine, Scotland, UK) were dissolved in 0.9% saline and administered as 
an i.p. injection. All doses are base equivalent weight and were administered in a volume 
of 1 mL/kg.  
 
Protocols 
Operant Training  
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Following habituation to the operant chambers, rats were trained to respond for food on a 
fixed ratio 1 (FR1) schedule of reinforcement with both levers active, as described in 
detail previously [2]. Rats were trained to press either the left or right lever for food 
delivery according to a visual cue (LED on or off). The experimental session was 
terminated following a total of 128 lever presses, which took approximately 30 minutes. 
Rats were trained once daily for 5 days, and this was repeated until rats had reached 
criterion (ie, 90% correct responding for 3 consecutive days).  
The day before each reversal-learning session, a full 30-minute operant training 
session (as described above) was conducted to ensure stable responding (ie, 90% correct 
responding). The reversal-learning session involved animals being first exposed to a 5-
miuten period during which the active lever was the same as on the previous training day. 
During this period, responses on both correct and incorrect levers were recorded. This 
part of the session was the initial phase. This was followed by a 2-minute time-out period, 
which was signalled by the house light being turned off. The 2-minute time-out period 
acts as a cue that the rule is about to change. In the subsequent 5-minute period, the active 
lever was reversed. Responses made on the correct and incorrect levers were again 
recorded. This second period was the reversal phase. Animals undertook several of these 
reversal-learning sessions before beginning the drug studies to ensure that they attained a 
stable level of performance (ie, 90% correct responding and at least 25 lever presses in 
total, in both the initial and reversal phases of the task). 
 
Studies 1a and 1b: Effects of Acute Intervention on Deficits Induced by Acute D-
Amphetamine or PCP 
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Rats were tested on a cycle of 4 days. On day 1, each animal had a 30-minute operant 
training session. The following day, animals received the appropriate drug(s) and 
undertook a reversal-learning session. On day 3 and day 4, each animal underwent a 
further operant training session and reversal-learning session, respectively, to ensure that 
normal responding was regained following drug treatment. If responding was not 
normalized, the 4-day cycle was repeated. The order of treatment exposure was 
determined randomly for each rat. This cycle of testing has previously been described in 
detail [25]. For drug treatments we used 9 to 10 rats per treatment. The PCP (1.5 mg/kg) 
and D-amphetamine (0.75 mg/kg) doses used were chosen based on previous studies 
[2,25]. Both were administered 30 minutes before testing. Based on preliminary tests with 
asenapine (0.003–0.1 mg/kg s.c.) that assessed effects on spontaneous locomotor activity, 
doses of asenapine (0.025, 0.05, and 0.075 mg/kg s.c.) were chosen that were expected to 
have minimal effects on motor function. The asenapine doses and s.c. route used in these 
studies were also based on studies demonstrating D2 receptor occupancy in rat brain [46] 
and demonstrating antipsychotic-like activity in established neurochemical and 
behavioral paradigms [15,23,54]. Asenapine was administered 40 minutes before testing 
and 10 minutes before PCP or D-amphetamine. The risperidone (0.05, 0.1, and 0.2 mg/kg 
i.p.) and olanzapine (0.5, 1.0, and 1.5 mg/kg i.p.) doses were also based on previous 
studies from this laboratory [3,18,39] and do not exceed the range that is suggested to be 
clinically relevant, based on dopamine D2 receptor occupancy in rat brain [31]. 
Olanzapine and risperidone were given 45 minutes before testing and 15 minutes before 
PCP or D-amphetamine. 
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Study 2: Effects of Acute Intervention on Deficits Induced by Subchronic PCP 
After completion of reversal-learning training as described above, another group 
of rats was treated twice daily for 7 days with PCP 2 mg/kg (n=40) or 0.9% saline at 1 
mL/kg (n=10). The PCP dose was chosen based on previous work in our laboratory 
demonstrating robust and enduring cognitive and social behavior deficits [1,3,18,39,49]. 
During PCP treatment and the subsequent 7-day drug-free period, reversal-learning 
sessions were discontinued to prevent the development of an association between PCP 
treatment and the reinforcement contingencies of the reversal-learning task and to ensure 
that PCP-induced deficits were enduring and not related to acute PCP withdrawal. 
Treatment with asenapine, risperidone, olanzapine, and respective vehicles was 
performed according to the same 5-day cycle and procedures described for study 1. 
Overall, it took 3 to 4 weeks complete this study. 
 
Study 3: Effects of Chronic Intervention on Deficits Induced by Subchronic PCP 
After completing study 2, the same rats then continued to be treated for 28 days 
with twice-daily asenapine 0.075 mg/kg, once-daily risperidone 0.2 mg/kg, once-daily 
olanzapine 1.5 mg/kg, or vehicle. Because it took 3 to 4 weeks to complete study 2, 
chronic treatment during study 3 was initiated approximately 4 to 5 weeks after 
subchronic PCP treatment had ended. 
In vehicle- and asenapine-treated rats, injections were administered at 8:00 AM 
and 4:00 PM. In risperidone- and olanzapine-treated rats, drug injections were 
administered at 8:00 AM, and an additional vehicle injection was administered at 4:00 PM. 
Performance was assessed on treatment days 3, 7, 14, 17, 21, and 28, as well as 1 day 
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after chronic treatment ceased. Testing followed the 8:00 AM treatment on all test days, 
except for day 17, when testing preceded treatment to ensure that any improvements in 
performance were the result of chronic treatment and not acute treatment effects.  
 
Statistical Analysis 
Accuracy (indexed by the percentage of correct responses) and total session 
responses were recorded during each phase of the task. All data are reported as the mean 
 standard error. Accuracy data were arcsin-transformed [arcsin (square root percentage 
correct responses)] before statistical analysis. Total responding (ie, lever presses) was 
used to assess the potential nonspecific motor, arousal, or motivational effects of 
treatment (data not shown). Overall, the effects of treatment on total session responding 
were small (generally <10%) and unlikely to contribute to changes in the main endpoint 
(ie, accuracy).  
In studies 1 and 2, initial- and reversal-phase performance data were assessed 
using 1-way analysis of variance (ANOVA). In study 3, performance during the initial 
and reversal phases was assessed independently based on the results of studies 1 and 2 
and previously published reports [1,3] indicating that subchronic PCP does not alter 
performance during the initial phase of this task. Data were analyzed by 2-way ANOVA 
with day of treatment as the within-subject factor and drug treatment as the between-
subjects factor. When appropriate, all pairwise post hoc comparisons were conducted 
using Dunnett t test, and statistical significance was defined as P<0.05. 
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RESULTS  
Study 1a: Acute Intervention Effects on Acute D-Amphetamine–Induced Deficit 
Effects of Asenapine 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,48)=0.08, P=0.99]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,48)=4.29, P<0.01]. Post hoc analysis revealed that accuracy 
was significantly reduced by D-amphetamine compared to the vehicle-treated group 
(P<0.01, Figure 1A). Asenapine did not significantly reverse the deficit in accuracy 
induced by D-amphetamine (Figure 1A). Asenapine at 0.075 mg/kg decreased total 
responding compared with the vehicle group from approximately 26 lever presses to 23 
(data not shown). 
 
Effects of Risperidone 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,48)=0.09, P=0.98]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,48)=4.28, P<0.01]. Post hoc analysis revealed that accuracy 
was significantly reduced by D-amphetamine compared with the vehicle-treated group 
(P<0.01, Figure 1B). Risperidone at 0.2 mg/kg significantly reversed the deficit in 
accuracy induced by D-amphetamine (P<0.05, Figure 1B). Risperidone did not affect 
total session responding during either phase (data not shown). 
 
Effects of Olanzapine 
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Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,48)=0.09, P=0.98]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,48)=5.59, P<0.001]. Post hoc analysis revealed that accuracy 
was significantly reduced by D-amphetamine compared with the vehicle-treated group 
(P<0.001, Figure 1C). Deficits induced by D-amphetamine were not reversed by 
olanzapine (Figure 1C), and total responding was unaffected in either phase (data not 
shown).  
 
Study 1b: Acute Intervention Effects on Acute PCP-Induced Deficit 
Effects of Asenapine 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,49)=1.16, P=0.34]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,49)=7.38, P<0.001]. Post hoc analysis revealed that accuracy 
was significantly reduced by PCP compared with the vehicle-treated group in the reversal 
phase (P<0.001, Figure 2A). All asenapine doses significantly attenuated PCP-induced 
deficits in reversal performance (P<0.05–0.01, Figure 2A). Asenapine at 0.075 mg/kg 
decreased total responding compared with the vehicle group from approximately 26 lever 
presses to 19 (data not shown). 
 
Effects of Risperidone 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,49)=0.34, P=0.85]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,49)=7.73, P<0.001]. Post hoc analysis revealed that accuracy 
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was significantly reduced by PCP compared with the vehicle-treated group in the reversal 
phase (P<0.001, Figure 2B). Risperidone at 0.2 mg/kg significantly reversed the PCP-
induced accuracy deficit (P<0.01) and restored accuracy to levels observed following 
vehicle (Figure 2B). Risperidone at 0.1 mg/kg and 0.2 mg/kg decreased total responding 
in both phases compared with all other treatments (data not shown). 
 
Effects of Olanzapine 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,49)=0.38, P=0.82]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,49)=4.51, P<0.01]. Post hoc analysis revealed that accuracy 
was significantly reduced by PCP compared with the vehicle-treated group in the reversal 
phase (P<0.01, Figure 2C). Olanzapine at 1.0 mg/kg significantly reversed the PCP-
induced accuracy deficit (P<0.05). Olanzapine at 1.5 mg/kg did not significantly improve 
performance compared with PCP treatment (P=0.078), but this trend suggested that there 
was some partial reversal of the effects of PCP. Olanzapine at the dose range tested did 
not alter total responding during either phase (data not shown). 
 
Study 2: Acute Intervention Effects on Subchronic PCP-Induced Deficit 
Effects of Asenapine 
Statistical analysis of accuracy revealed a significant interaction in the initial 
phase [F(4,44)=3.53, P<0.05]; however, post hoc comparisons did not reveal any 
significant difference from the vehicle-treated group. A 1-way ANOVA in the reversal 
phase showed a significant interaction [F(4,44)=5.17, P<0.01]. Post hoc analysis revealed 
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that accuracy was significantly reduced by subchronic PCP compared with the vehicle-
treated group in the reversal phase (P<0.001, Figure 3A). Asenapine at 0.075 mg/kg 
significantly attenuated this PCP-induced deficit (P<0.05, Figure 3A) and restored 
accuracy to a level observed with vehicle. After asenapine at 0.05 mg/kg, a trend toward 
a reversal of PCP-induced deficits was also observed (P=0.083). Asenapine at 0.075 
mg/kg decreased total responding compared with the vehicle group from approximately 
26 lever presses to 23 (data not shown). 
 
Effects of Risperidone 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,44)=2.18, P=0.09]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,44)=5.97, P<0.01]. Post hoc analysis revealed that accuracy 
was significantly reduced by subchronic PCP compared with the vehicle-treated group in 
the reversal phase (P<0.001, Figure 3B). Risperidone at 0.2 mg/kg significantly 
attenuated this PCP-induced deficit (P<0.05, Figure 3B). At the dose range tested 
risperidone did not affect total session responding during either phase (data not shown). 
 
Effects of Olanzapine 
Statistical analysis of accuracy revealed that there was no interaction in the initial 
phase [F(4,44)=0.25, P=0.91]. A 1-way ANOVA in the reversal phase showed a 
significant interaction [F(4,44)=13.16, P<0.001]. Post hoc analysis revealed that accuracy 
was significantly reduced by subchronic PCP compared with the vehicle-treated group in 
the reversal phase (P<0.001, Figure 3C). Olanzapine at 0.5 mg/kg and 1.5 mg/kg 
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significantly attenuated the subchronic PCP–induced deficit (P<0.05 and P<0.001, 
respectively), with olanzapine at 1.5 mg/kg fully reversing the effects of subchronic PCP 
(Figure 3C). At the dose range tested olanzapine did not affect total session responding 
during either phase (data not shown). 
 
Study 3: Chronic Intervention Effects on Subchronic PCP-Induced Deficit 
Effects of Asenapine 
A 2-way ANOVA in the reversal phase with day of treatment as the within-
subject factor and drug treatment as the between-subjects factor showed a significant 
interaction [F(2,25)=13.46, P<0.001]. Accuracy was significantly reduced by subchronic 
PCP treatment compared with the vehicle-treated group on days 3 (P<0.001), 7 (P<0.01), 
17 (P<0.01), and 21 (P<0.05), and reduced to a level closely approaching significance on 
day 28 (P=0.063). Accuracy of PCP-treated rats was significantly improved by asenapine 
(0.075 mg/kg) on days 3 (P<0.01), 7 (P<0.05), and day 17 (P<0.05) when testing 
occurred 16 hours after the last asenapine treatment and to a level approaching 
significance on day 28 (P=0.078). Asenapine did not affect total session responding 
during either phase of the test (data not shown). 
 
Effects of Risperidone 
A 2-way ANOVA in the reversal phase with day of treatment as the within-subject factor 
and drug treatment as the between-subjects factor showed a significant interaction 
[F(2,25)=9.90, P<0.01]. Accuracy was significantly reduced by subchronic PCP 
treatment compared with the vehicle-treated group on days 3 (P<0.001), 7 (P<0.01), 17 
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(P<0.05), 21 (P<0.05), and 28 (P<0.05). Accuracy of PCP-treated rats was significantly 
improved by risperidone (0.2 mg/kg) on days 3 (P<0.01), 7 (P<0.05), and 28 (P<0.05) 
and to a level approaching significance on day 17 (P=0.083) when testing occurred 24 
hours after the last risperidone treatment.  Risperidone did not affect total session 
responding during either phase of the test (data not shown). 
Effects of Olanzapine 
A 2-way ANOVA in the reversal phase with day of treatment as the within-
subject factor and drug treatment as the between-subjects factor showed a significant 
interaction [F(2,25)=11.69, P<0.001]. Accuracy was significantly reduced by subchronic 
PCP treatment compared with the vehicle-treated group on days 3 (P<0.001), 7 (P<0.01), 
17 (P<0.01), 21 (P<0.05), and 28 (P<0.05). Accuracy of PCP-treated rats was 
significantly improved by olanzapine (1.5 mg/kg) on days 3 (P<0.01) and 17 (P<0.05) 
when testing occurred 24 hours after the last olanzapine treatment; accuracy was 
improved to a level closely approaching significance on day 7 (P=0.058).  Olanzapine did 
not affect total session responding during either phase of the test (data not shown). 
 
 
DISCUSSION  
The main findings of these studies demonstrate that acute administration of either 
D-amphetamine or PCP produces a reproducible and selective deficit in cued reversal 
learning that is attenuated by risperidone, whereas asenapine and olanzapine were 
effective against the deficit produced by PCP but not against the deficit produced by D-
amphetamine. Subchronic PCP administration across independent experiments produced 
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a reproducible and selective deficit in cued reversal learning, which endured for up to 4 
weeks after the cessation of PCP treatment. This effect of PCP was most prominent in the 
first week of testing, and was maintained as a partial impairment over the next 3 weeks of 
testing. The impairment was abolished following acute administration of asenapine and 
olanzapine, and after chronic administration of asenapine, risperidone, and olanzapine. 
This improvement in performance was maintained when animals were tested on day 17, a 
minimum of 16 hours after antipsychotic treatment which may have important 
implications for therapy. Recent studies from this laboratory have demonstrated that 
SGAs do not generally have any effect on reversal learning in non-impaired rats [2,3,25]. 
Therefore, it is hypothesized that the effects of asenapine, risperidone, and olanzapine 
observed in these studies represent an “attenuation” or “reversal” of the impairment 
produced by PCP or D-amphetamine. 
The subchronic PCP studies add to the existing literature on this model by 
providing insight on the persistent nature of PCP-induced cognitive dysfunction, as well 
as its reversibility by chronic drug treatment. Furthermore, the acute-treatment studies 
provide detailed dose-effect analyses for the drugs used in 2 mechanistically distinct 
models of cognitive dysfunction.  
The assessment of within-session cued reversal learning in these studies is 
relatively novel when compared with other models that employ between-session 
assessments and within-session reversal learning [10,13,30]. The main advantage of this 
within-session cued reversal-learning model is that it allows for the rapid assessment of 
reversal-learning performance, with the appropriate reversal of behavior being observed 
over the course of a small number of trials. Despite this procedural difference, the ability 
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of the tested agents to reverse PCP-induced deficits was consistent with previous reports 
of the cognitive-enhancing effects of SGAs in animal models in general 
[11,13,18,28,29,39] and in different types of reversal-learning tasks [10,28]. Furthermore, 
these data are fully consistent with the effects of other SGAs and novel antipsychotics 
that have been observed in this reversal-learning task [1-3,25]. 
In these studies, the effects of drug treatment were selective for the reversal phase. 
Psychotomimetics, asenapine, risperidone, and olanzapine had no impact on accuracy 
during the initial phase of the task. The effects of D-amphetamine and PCP were robust 
and reproducible, supporting previous studies on reversal learning [1-3,25]. Although all 
treatments had some impact on total session responding, the magnitude of the treatment 
effects was generally small, suggesting that nonspecific treatment effects are unlikely to 
influence overall performance of the task. The inconsistent pattern of reductions across 
studies also supports this interpretation.  
Asenapine did not significantly attenuate D-amphetamine-induced deficit at 0.075 
mg/kg, suggesting modest antidopaminergic activity at the dose range tested. A similar 
profile was observed with olanzapine; however, a more robust effect was observed with 
risperidone, indicating strong dopaminergic blockade with this agent at the dose range 
tested. This is consistent with the higher D2 receptor affinity of risperidone compared 
with that of olanzapine [47]. However, asenapine and risperidone have similar D2 
receptor affinities [46], suggesting that some other aspect of the receptor pharmacology 
of asenapine may moderate its in vivo antidopaminergic action. In agreement with this, 
asenapine has recently been shown to have antidopaminergic activity in other models, 
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such as amphetamine-induced hyperactivity [36]. Our apparent lack of such an effect may 
be due to the nature of the test procedure and the mechanism of action of asenapine. 
PCP, given as a single injection, produced a robust and reproducible deficit in 
reversal learning in a manner consistent with previous reports from this laboratory [2,25]. 
Asenapine attenuated the effects of PCP at all doses tested, whereas the effects of 
olanzapine and risperidone were not observed at the lower doses tested. However, direct 
comparisons of the potency of asenapine versus olanzapine and risperidone should be 
made cautiously because their routes of administration differed in these studies.  
Results from the subchronic PCP study are also consistent with previous reports 
of atypical antipsychotics [1,3]. Both acute and chronic asenapine treatment attenuated 
the reversal-learning deficit produced by subchronic PCP treatment. Olanzapine and 
risperidone showed a similar profile of effect. The attenuation of reversal-learning 
deficits by these agents does not seem to be solely attributed to their ability to attenuate 
deficits after acute exposure. On day 17, when testing was done 16 to 24 hours after the 
last drug treatment, performance was still enhanced in PCP-exposed rats treated with 
asenapine, olanzapine, or risperidone compared with PCP-exposed rats treated with 
vehicle. The implication is that chronic treatment with these agents may produce 
enduring changes that mitigate the effects of subchronic PCP treatment. Taken together, 
these data demonstrate that asenapine, like risperidone and olanzapine, is capable of 
attenuating cognitive dysfunction caused by repeated exposure to PCP. 
In reversal-learning tests, animals are required to acquire a new strategy and in 
doing so demonstrate the ability to maintain attention and motivation, suppress a 
previously learned response, and implement a new response. Jentsch et al [28] 
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demonstrated that PCP selectively impairs the ability of rats to reverse an already-learned 
stimulus-reward association. The disruption induced by PCP in the study by Jentsch et al 
[28] was characterized by perseveration on the previously acquired stimulus-reward 
association, a profile that echoes the perseveration seen in patients with schizophrenia 
performing the Wisconsin card-sorting test [12]. Thus, psychotomimetic-induced deficits 
in reversal learning or switching tasks in animals may be useful for modeling cognitive 
deficits that reflect prefrontal cortical dysfunction in patients with schizophrenia. In this 
regard, the operant reversal-learning paradigm used in the present studies demonstrates 
good predictive validity. PCP-induced reversal-learning impairments in rats are 
attenuated by asenapine (as shown in the present study), risperidone, olanzapine (as 
shown in the present study and previously [3]), and ziprasidone [2,3]. These same agents 
demonstrate some efficacy in improving neurocognition in patients with schizophrenia 
[14,32]. It is of interest to note that although antipsychotics have demonstrated cognitive-
enhancing effects in patients with schizophrenia, the effects have generally been found to 
be small and inadequate [17,32,42], whereas effects in animal models have been more 
consistent and more pronounced. The reasons for discrepancies between cognitive 
efficacy in patients with schizophrenia and animal models are not fully understood. 
Potential contributing factors may include the heterogeneous populations assessed in 
clinical trials versus the homogenous populations used in rodent studies; previous drug 
therapy in patients and not in rodents (in rodents, studies are typically performed in 
antipsychotic naive subjects); the assessment tools used in clinical versus preclinical 
studies; differences between treating a chronic disorder versus a drug-induced deficit, 
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albeit a robust and long-lasting deficit; and species differences in the effects of these 
agents.  
The ability of asenapine, olanzapine, and risperidone to attenuate PCP-induced 
cognitive deficits may be a function of their modulation of dopaminergic and 
glutamatergic activity through antagonism of 5-HT receptor subtypes. In rat and monkey 
models, acute treatment with PCP produces dopaminergic hyperactivity in frontal cortical 
regions, whereas repeated PCP treatment decreases cortical dopaminergic activity 
[26,29]. Antagonism of the 5-HT2A receptor selectively regulates mesocortical dopamine 
projections, with both asenapine and the selective 5-HT2A antagonist M100907 increasing 
prefrontal cortical dopamine release [15,45]. Thus, drugs that block 5-HT2A receptors 
within the prefrontal cortex may increase dopamine transmission and consequently 
alleviate subchronic PCP–induced cognitive dysfunction. Alternatively, the ability of 
asenapine and the other drugs to attenuate PCP-induced deficits in reversal learning could 
be related to influences on glutamatergic activity. PCP and other NMDA antagonists 
increase 5-HT release in the prefrontal cortex [37], which may lead to excessive 
glutamatergic activity [5]. Excessive prefrontal cortical glutamatergic activity associated 
with enhanced 5-HT efflux is also reversed by antagonism at the 5-HT2A receptor [6]. In 
regard to 5-HT receptor antagonism, asenapine also displays high affinity for the 5-HT2C, 
5-HT6, 5-HT7 receptors [47], which may be of relevance to its ability to attenuate PCP-
induced cognitive dysfunction. This is based on demonstration that selective 5-HT2C, 5-
HT7 [40], and 5-HT6 [21,22] receptor antagonists have cognition-enhancing effects in 
animal models. Indeed, it could be speculated that the combined potent and broad 
serotonergic antagonism by asenapine may be the important feature with regard to its 
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mechanism underlying the efficacy in models of cognitive dysfunction. A recent study 
supports our findings and demonstrates a pro-cognitive effect of asenapine in animals 
with prefrontal cortical lesions, which has particular relevance for schizophrenia [52]. 
In summary, the current studies further demonstrate that psychotomimetic-
induced impairment in reversal learning in the rat serve as models for mimicking certain 
aspects of cognitive deficits in schizophrenia. Asenapine potently and robustly attenuated 
reversal-learning deficits induced by acute PCP but not D-amphetamine. It also offset the 
enduring reversal-learning deficit induced by subchronic PCP treatment, with no 
evidence of decreased effectiveness over time. Similar profiles were seen with chronic 
administration of risperidone and olanzapine. Uniquely strong antiserotonergic properties 
(eg, high affinity for 5-HT2A 5-HT2c, 5-HT6, and 5-HT7 receptors) may be a key driver in 
the mode of action of asenapine. It is concluded that the improvement seen with 
asenapine in the rat PCP-induced reversal-learning deficit model is comparable to that of 
risperidone and olanzapine. The clinical relevance of the current findings for asenapine in 
the treatment of cognitive deficits associated with schizophrenia remain to be established. 
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Figure Legends 
 
Figure 1. Acute effects of (A) asenapine, (B) risperidone, and (C) olanzapine on response 
accuracy after acute D-amphetamine (d-amph) treatment (0.75 mg/kg). Data represent the 
mean ± SE of the mean (n=9–10 per group). Significant difference from vehicle (veh) + 
veh in the same phase (Dunnett t test: **P≤0.01, ***P≤0.001). Significant difference 
from veh + d-amph in the same phase (Dunnett t test: 
#
P≤0.05). 
 
Figure 2. Acute effects of (A) asenapine, (B) risperidone, and (C) olanzapine on response 
accuracy after acute phencyclidine (PCP) treatment (1.5 mg/kg). Data represent the mean 
± SE of the mean (n=10 per group). Significant difference from vehicle (veh) + veh in the 
same phase (Dunnett t test: **P≤0.01, ***P≤0.001). Significant difference from veh + 
PCP in the same phase (Dunnett t test: 
#
P≤0.05, ##P≤0.01). 
 
Figure 3. Acute effects of (A) asenapine, (B) risperidone, and (C) olanzapine on response 
accuracy after 7 days of phencyclidine (PCP; 2 mg/kg twice daily) treatment followed by 
7 days of washout. Data represent the mean ± SE of the mean (n=8–10 per group). 
Significant difference from vehicle (veh) + veh in the same phase (Dunnett t test: 
***P≤0.001). Significant difference from veh + PCP in the same phase (Dunnett t test: 
#
P≤0.05, ###P≤0.001). 
 
Figure 4. Chronic effects of (A) asenapine (0.075 mg/kg), (B) risperidone (0.2 mg/kg), 
and (C) olanzapine (1.5 mg/kg) on response accuracy after 7 days of phencyclidine (PCP) 
treatment. Data represent the mean ± SE of the mean (n=8–10 per group). Significant 
difference from vehicle (veh) + veh in the same phase (Dunnett t test: *P≤0.05, 
**P≤0.01, ***P≤0.001). Significant difference from PCP + antipsychotic in the same 
phase (Dunnett t test: 
#
P≤0.05, ##P≤0.01). 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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